Plain-English translation of NCT06951074 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new approach to type 1 diabetes using autologous insulin-producing mesenchymal stem cell transplantation. Researchers will take stem cells from your own fat tissue, grow them in the lab to become insulin-producing cells, and then transplant them back into your body. The goal is to help your body produce insulin again and reduce your need for insulin injections.
Type 1 diabetes occurs when the pancreas stops making insulin. This treatment aims to restore the body's natural ability to produce insulin by transplanting specially grown cells, potentially reducing dependence on daily insulin therapy and improving blood sugar control.
You likely qualify if…
You likely don't qualify if…
You would undergo a procedure to collect fat tissue, which is then sent to a laboratory where your stem cells are grown and transformed into insulin-producing cells. Once ready, these cells would be transplanted back into your body through an injection into either your portal circulation (the blood vessels in your liver) or your regular bloodstream. After transplantation, you would be monitored to see if the new cells produce insulin and help control your blood sugar levels.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Egypt
Sponsor
Ain Shams University
Enrollment target
~20 participants
Started
April 2025
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
15 Years – 18 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rasha S Elmetwally, MD
Assistant professor of Pediatrics, Faculty of Medicine, Ain Shams University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.